Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-75
SponsorShanghai Gynecologic Oncology Group
About this trial
The purpose of this study is to evaluate the safety and the effectiveness of hepato-celiac lymphadenectomy in the treatment of primarily diagnosed advanced epithelial ovarian cancer and platinum-sensitive recurrent ovarian cancer.
Eligibility criteria
Qualifiers
Age ≥18 years to ≤ 75 years.
Pathologic confirmed stage III or IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal carcinoma (EOC, PPC, FTC) or platinum sensitive, relapsed EOC, PPC or FTC (no more than 4 lines of therapy)
Hepato-celiac lymph nodes metastases diagnosed by imaging before surgery and enlarged palpable lymph nodes by surgical findings
Assessed by the experienced surgeons, complete resection is feasible according to preoperative evaluation
Disqualifiers
Patients with non-epithelial ovarian cancer, fallopian tube cancer or primary peritoneal carcinoma.
Low-grade carcinoma.
Mucinous ovarian cancer.
Infeasible complete resection according to preoperative evaluation
Trial design
Treatments tested in this trial
- Hepato-celiac lymphadenectomy
Treatment groups
94 Participants
are divided into 1 treatment groupSponsors and collaborators
Shanghai Gynecologic Oncology Group
Lead sponsor
Fudan University
Collaborator
Source ClinicalTrials.gov